- Astellas Pharma (ALPMY.PK) reports FQ1 consolidated net sales of ¥275.8B (.pdf), up 13.4% Y/Y.
- Net sales of Xtandi — the prostate cancer treatment developed and commercialized with partner Medivation (MDVN) — were $82M for the period, below Street estimates of $83.7M. (supplemental documents)
- Xtandi faces what some say is looming threat from Janssen's acquisition of Aragon and the company's ARN-509.
Astellas reports, Xtandi sales in focus for Medivation
Aug 1 2013, 08:21 ET